Skip to main content
Figure 2 | Diabetology & Metabolic Syndrome

Figure 2

From: CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models

Figure 2

CNX-013-B2 improves insulin sensitivity and glucose tolerance in ob/ob mice. A- OGTT in ob/ob mice at week 4 of treatment. Circle-Lean, Square-ob/ob and Triangle-CNX-013-B2 (10 mpk, bid). B- glucose AUC (0–180 min), C- Fasting (6 h) insulin, D- fed insulin levels, E- p-JNK in liver, F- p-AKT levels in inguinal adipose. All the values are expressed as Mean ± SEM; one way analysis of variance followed by Dunnett’s post hoc test for representing significance value of the treatment groups. P value significance was represented as (*) <0.05, (**) <0.01 and (***) <0.001 when compared with ob/ob control. (#) <0.05 and (##) <0.01 as compared to ob/+.

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us